D
Dan Lindholm
Researcher at Minerva Foundation Institute for Medical Research
Publications - 266
Citations - 25963
Dan Lindholm is an academic researcher from Minerva Foundation Institute for Medical Research. The author has contributed to research in topics: Nerve growth factor & Neurotrophic factors. The author has an hindex of 70, co-authored 235 publications receiving 23924 citations. Previous affiliations of Dan Lindholm include University of Melbourne & Max Planck Society.
Papers
More filters
Journal ArticleDOI
The maraca plot: A novel visualization of hierarchical composite endpoints
TL;DR: In this paper , a novel maraca plot is proposed for visualization of hierarchical composite endpoints consisting of several time-to-event outcomes and a continuous outcome, which combines violin plots (with nested box plots) to visualize the density of the distribution of the continuous outcome and Kaplan-Meier plots for time to event outcomes into a comprehensive visualization.
pathway lymphoblastic leukemia cells to dexamethasone via an Akt-dependent Low dose arsenic trioxide sensitizes glucocorticoid-resistant acute
Felix Niggli,Beat W. Schäfer,Jean-Pierre Bourquin,Beat Bornhauser,Laura Bonapace,Dan Lindholm,Rodrigo Martinez,Gunnar Cario,Martin Schrappe +8 more
TL;DR: The potential of arsenic trioxide (ATO) to restore the response to dexamethasone in glucocorticoid (GC)-resistant acute lymphoblastic leukemia (ALL) is tested and the combination of ATO and glucoc Corticoids could be advantageous in GC-resistant ALL.
Journal ArticleDOI
Overexpression of the X-Linked Inhibitor of Apoptosis Protein (XIAP) in Neurons Improves Cell Survival and the Functional Outcome after Traumatic Spinal Cord Injury
David Reigada,Rodrigo M. Maza,Teresa Muñoz-Galdeano,M. Asunción Barreda-Manso,Altea Soto,Dan Lindholm,R Navarro-Ruiz,Manuel Nieto-Díaz +7 more
TL;DR: Xia et al. as discussed by the authors showed that the elevation of X-linked inhibitor of apoptosis protein (XIAP) resulted in increased neuronal survival after spinal cord injury and improved functional recovery.
Journal ArticleDOI
Author Correction: Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial.
Orly Vardeny,James C. Fang,Akshay S. Desai,Pardeep S. Jhund,Brian Claggett,Muthiah Vaduganathan,W. De Boer,Adrian F. Hernandez,Carolyn S.P. Lam,Silvio E. Inzucchi,Felipe Martinez,Mikhail Kosiborod,David L. DeMets,Eileen O'Meara,Shelley Zieroth,Josep Comín-Colet,Jarosław Drożdż,Chern-En Chiang,Masafumi Kitakaze,Magnus Petersson,Dan Lindholm,Anna Maria Langkilde,John J.V. McMurray,Scott D. Solomon +23 more